Is lorlatinib/lorlatinib included in medical insurance?

Lorlatinib/lorlatinib ( Lorlatinib), an innovative drug, has been officially launched in China, has been recognized by the National Medical Insurance Bureau, and has been included in the Class B medical insurance reimbursement catalog. For patients who meet the indications, as long as the prescription is prescribed by an experienced oncologist, they can be reimbursed by the national medical insurance.

Lorlatinib is a multifunctional kinase inhibitor that not only effectively inhibitsALK and ROS1, but also has in vitro activity against TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2 and ACK. It is worth mentioning that lorlatinib has demonstrated inhibitory effects on multiple mutant forms of the ALK enzyme in in vitro experiments, including some that are resistant to crizotinib and other ALK inhibitors.

In animal models, lorlatinib also demonstrated significant anti-tumor activity. In mouse tumor models containing EML4-ALK fusions or ALK mutations, lorlatinib has shown strong anti-tumor effects and the potential to extend survival whether implanted subcutaneously or intracranially.

With the launch of lorlatinib in the domestic market and its entry into the medical insurance catalog, patients now have more treatment options and financial security. Currently, the common specifications of lorlatinib on the market include 25 mg × 90 tablets and 100 mg × 30 tablets. Although the high cost of research and development of new drugs makes their market prices relatively high, with each box selling for about 10,000 to 20,000 yuan, the actual burden on patients will be significantly reduced thanks to the medical insurance reimbursement policy. The specific reimbursement ratio and amount may vary from region to region, and patients are advised to directly consult their local hospital or medical insurance bureau to obtain the most accurate information.